阿司匹林联合华法林对冠心病合并心房纤颤患者的安全性和有效性分析  

Aspirin combined with warfarin for patients with coronary heart disease complicated with atrial fibrillation

作　　者：陈硕 何荣华[1] 邱俊英[1] 饶国涛[1] 王琼涛[1] 鲁志科[1] 张进锋 李鹏飞 Chen Shuo;He Ronghua;Qiu Junying;Rao Guotao;Wang Qiongtao;Lu Zhike;Zhang Jinfeng;Li Pengfei(Department of Cardiovascular Medicine,Xiaogan Central Hospital,Xiaogan 432000,China)

机构地区：[1]孝感市中心医院心血管内科,432000

出　　处：《国际医药卫生导报》2019年第14期2326-2327,共2页International Medicine and Health Guidance News

摘　　要：目的探讨阿司匹林联合华法林在冠心病合并心房纤颤患者中的影响。方法选取2017年1月至2018年2月本院收治的冠心病合并心房纤颤患者107例作为观察对象,分为观察组52例和对照组55例。观察组采用阿司匹林联合华法林治疗,对照组单用华法林治疗。统计两组的血栓事件发生情况及出血事件发生情况。结果观察组血栓栓塞发生率3.85%(2/52),低于对照组16.36%(9/55),差异有统计学意义(P<0.05);两组出血事件发生率比较,差异无统计学意义(P>0.05)。结论冠心病合并心房纤颤患者应用阿司匹林联合华法林治疗,能降低血栓栓塞风险,出血风险并未叠加,保证了用药安全性。Objective To investigate the effect of aspirin combined with warfarin for patients with coronary heart disease and atrial fibrillation. Methods 107 patients with coronary heart disease and atrial fibrillation admitted to our hospital were divided into an observation group (aspirin combined with warfarin group) and a control group (warfarin group). The situation and occurrence of bleeding events were recorded and analyzed. Results The incidence of thromboembolism was lower in the observation group than in the control group [3.85%(2/52) vs.16.36%(9/55);P < 0.05]. There was no statistical difference in the incidence of bleeding events between the two groups (P > 0.05). Conclusion Aspirin combined with warfarin for patients with coronary heart disease and atrial fibrillation can reduce the risk of thromboembolism, and the risk of bleeding is not superimposed, which ensures the medication safety.

关 键 词：心房纤颤 阿司匹林 华法林 

分 类 号：R541.4[医药卫生—心血管疾病] R541.75[医药卫生—内科学]